EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis

Xiaohui Fang, Yuhang Yin, Qinke Wu, Lu Chai, Yifan Guo, Zhenhua Tong, Nahum Méndez-Sánchez iD, Xingshun Qi iD

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2600410 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Xiaohui Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The General Hospital of Northern Theater Command (Teaching Hospital of Shenyang Pharmaceutical University), Shenyang,…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: the Liaoning Provincial Science and Technology Plan Joint Plan, LiaoNing Revitalization Talents Program, Independent Research Funding of General Hospital of Northern Theater Command.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Nonalcoholic fatty liver diseases (NAFLD) and metabolic dysfunction-associated fatty liver diseases (MAFLD) are closely associated with metabolic syndrome, including obesity, dyslipidemia, and insulin resistance (IR). Thus, stains may be considered for the management of NAFLD/MAFLD. However, its efficacy and safety remain unclear in NAFLD/MAFLD. METHODS: The PubMed, EMBASE, and Cochrane library databases were searched to identify randomized controlled trials (RCTs) evaluating the efficacy and/or safety of statins in NAFLD/MAFLD. Risk ratios (RRs) and weight mean differences (WMDs) with their 95% confidence intervals (CIs) were calculated. RESULTS: Seven studies involving 993 patients with NAFLD/MAFLD were included. Statins were significantly associated with reductions in alanine aminotransferase (ALT, WMD = -9.76 U/L, 95%CI: -17.28, -2.24, p = 0.010), aspartate aminotransferase (AST, WMD = -4.46 U/L, 95%CI: -9.03, 0.11, p = 0.060), gamma-glutamyl-transpeptidase (GGT, WMD = -10.18 U/L, 95%CI: -13.65, -6.70, p < 0.001), low-density lipoprotein (LDL, WMD = -0.86 mmol/L, 95%CI: -1.06, -0.66, p < 0.001), total cholesterol (TC, WMD = -0.88 mmol/L, 95%CI: -1.14, -0.61, p < 0.001), and triglyceride (TG, WMD = -0.32 mmol/L, 95%CI: -0.45, -0.19, p < 0.001) levels. Additionally, statins did not increase the risk of myalgia (RR = 0.96, 95%CI: 0.10, 9.00, p = 0.970). CONCLUSIONS: Statins could improve liver function and lipid profiles in NAFLD/MAFLD. No myalgia was reported as AEs in the studies we included and the overall safety was favorable.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42025630809.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsHumansRandomized Controlled Trials as TopicMetabolic SyndromeDyslipidemiasInsulin Resistance

Stichwörter der Autor:innen

Statinsefficacymetabolic dysfunction-associated fatty liver diseasesnonalcoholic fatty liver diseasessafety

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, The General Hospital of Northern Theater Command (Teaching Hospital of Shenyang Pharmaceutical University), Shenyang, China.
  • Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
  • Postgraduate College, China Medical University, Shenyang, China.
  • Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China.
  • Department of Research and Training, General Hospital of Northern Theater Command, Shenyang, China.
  • Liver Research Unit, Medica Sur Clinic and Foundation, National Autonomous University of Mexico, Mexico City, Mexico.

ORCID-Profile: Nahum Méndez-Sánchez, Xingshun Qi

Förderung

  • the Liaoning Provincial Science and Technology Plan Joint Plan
  • LiaoNing Revitalization Talents Program
  • Independent Research Funding of General Hospital of Northern Theater Command

Zitieren

APA

Fang, X., Yin, Y., Wu, Q., Chai, L., Guo, Y., Tong, Z., Méndez-Sánchez, N., & Qi, X. (2025). Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2600410

Vancouver

Fang X, Yin Y, Wu Q, Chai L, Guo Y, Tong Z, et al. Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2600410

BibTeX
@article{Fang2025,
  author = {Fang, Xiaohui and Yin, Yuhang and Wu, Qinke and Chai, Lu and Guo, Yifan and Tong, Zhenhua and Méndez-Sánchez, Nahum and Qi, Xingshun},
  title = {Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2600410}
}
Kostenlos starten →